Related Experiment Videos
[Clinical experience with cefoxitin in bacterial infections of children (author's transl)]
Insights
Cefoxitin, a new cephamycin antibiotic, showed an 80% efficacy rate in treating pediatric infections, including respiratory and urinary tract infections. This antibiotic demonstrated a favorable safety profile with minimal side effects in clinical studies.
Area of Science:
- Infectious Diseases
- Pediatrics
- Pharmacology
Context:
- Pediatric infections pose a significant health challenge.
- Novel antibiotic therapies are crucial for combating resistant pathogens.
- Cephamycin antibiotics offer a valuable class of antimicrobial agents.
Purpose:
- To evaluate the clinical efficacy and safety of cefoxitin in treating pediatric infections.
- To determine the appropriate dosage and administration route for cefoxitin in children.
- To assess the incidence and nature of adverse effects associated with cefoxitin therapy.
Summary:
- Cefoxitin was administered to 52 children (2 months to 11 years) with various infections, including respiratory and urinary tract infections.
- Intravenous cefoxitin dosages ranged from 27.3 mg/kg to 110.5 mg/kg daily.
- An overall efficacy rate of 80% was observed in 46 treated cases, with excellent or good responses in most patients.
Impact:
- Cefoxitin demonstrates significant potential as a safe and effective antibiotic for pediatric infections.
- The study highlights the need for continued research into cephamycin antibiotics for pediatric use.
- Findings support the use of cefoxitin in clinical settings for treating susceptible pediatric infections.
Abstract:
Using a new cephamycin antibiotic, cefoxitin, clinical studies were carried out, and the following results were obtained: (1) Cefoxitin was administered to 52 children with 38 respiratory tract infections, 2 urinary tract infections, 1 acute otitis media and others, who ranged in age from 2 months to 11 years old. (2) Cefoxitin was given intravenously at a daily dose of 27.3 mg/kg to 110.5 mg/kg. (3) The overall efficacy rate was 80% in 46 cases, i.e., excellent in 10, good in 27, fair in 7 and poor in 2. (4) Clinical side effects were not seen except exanthema in 1 patient. Elevation of GOT and GPT was seen in 2 patients, elevation of A1-P in 1 and eosinophilia in 2 by laboratory tests. However, these findings were alleviated rapidly following the cessation of therapy.